WiQo PRX PLUS® + WiQo Lightening Serum

PRX PLUS® + WiQo Lightening Serum — Complete Depigmentation Protocol Kit

This kit contains the two components of the official WiQo® depigmentation
protocol. PRX PLUS® and WiQo Lightening Serum target different phases of
the same biological process — and are clinically indicated to be used together.

What’s included

• PRX PLUS® — 1 box · 5 vials × 4 ml
  Up to 20 in-clinic sessions (1–1.5 ml per session, face and neck).
  Shelf life: 30 months (refrigerated storage).
• WiQo Lightening Serum — 1 bottle · 15 ml
  Home care. Applied 2× daily (morning and evening) throughout the
  full treatment cycle.

Mechanism of action

PRX PLUS® — In-clinic phase

PRX PLUS® is a next-generation no-needle biostimulation device. Its patented
formula replaces TCA with Ammonium Trichloroacetate (ATCA 33%) and hydrogen
peroxide with Homocysteic Acid (HoA 2%).

HoA is an NMDA receptor agonist exclusive to PRX PLUS®. It accelerates
epidermal turnover, pushing accumulated melanin to the surface for rapid
elimination. Simultaneously, it acts on melanocytes with a targeted depigmenting
effect — reducing existing spots and evening skin tone from within.

No needle. No ablation. No photosensitisation. Suitable for Fitzpatrick
skin types I–VI, year-round.

WiQo Lightening Serum — Home care phase

Formulated with tranexamic acid, ferulic acid, niacinamide, phytic acid,
sodium hyaluronate and licorice root extract. Acts as a melanin production
inhibitor — reducing the appearance of existing spots and preventing the
formation of new ones between and after sessions.

Without daily inhibition of melanin re-synthesis, re-pigmentation occurs
after the in-clinic phase. The Lightening Serum closes this gap, stabilising
and prolonging the depigmentation outcome.

Clinical data

PRX PLUS® — Independent instrumental analysis (n=30, 3 sessions over 2 weeks)

Analysis tools: Visia, Dermascope, Ultrasound L20 HD3

WiQo Lightening Serum

−36% hyperpigmentation score (in vitro test)

Safety profile — PRX PLUS®

0.0006% adverse event rate across over 8,000,000 applications worldwide.

Clinical indications

• Hyperpigmentation and uneven skin tone
• Melasma
• Age spots and UV spots
• Post-inflammatory hyperpigmentation (post-acne, post-burn)
• Advanced photoageing — deep wrinkles, dilated pores, irregular texture
• Oily and sebaceous skin

Official WiQo® protocol — Hyperpigmentation indication

In-clinic — PRX PLUS®

• 4 sessions, every 14 days
• Volume: 1–1.5 ml per session (face and neck)
• Session duration: 10–15 minutes
• Application: topical, specific massage technique — no needle

Home care — mandatory pairing

• WiQo Lightening Serum — 2× daily (morning and evening)
• WiQo Nourishing and Moisturizing Cream for Dry Skin
• WiQo Smoothing Fluid
• WiQo ICP Cream SPF 50+ (mandatory sun protection)

Follow-up and maintenance

• Assessment at day 45 post-cycle
• Second cycle from month 6 for stable long-term depigmentation

Packaging and storage